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Introduction: The multifloral Tualang honey (TH) and the monofloral Manuka honey (MH) 
have been reported to have antimicrobial, anti-inflammatory, antioxidant and anticancer effects. 
Unlike the MH, TH is not extensively studied. 
Objectives: This study was conducted to evaluate the mechanisms of the preventive and 
therapeutic effects of Tualang honey (TH), Manuka honey (MH) and honey sugars analogue 
(HSA) on experimental breast cancer induced rats using carcinogen 1-methyl-1-nitrosourea 
(MNU).  
Methodology: A total of 130 female Sprague-Dawley rats were used. Sixty female rats were 
randomly divided into 6 groups with 10 animals per group in each study. Group ‘0’ (negative 
control; normal rats); Group 1 (positive control; tumour induction but no treatment). Groups 2, 3 
and 4 were fed orally with 0.2, 1.0 and 2.0 g/kg body weight of TH. Group 5 received 1.0 g/kg of 
MH, and Group 6 received 1.0 g/kg HSA. For the “cancer-preventive” study, honey was given 
one week prior to MNU-induction and for the “cancer-therapeutic” study; treatment was given 
after breast cancer development. The treatment continued until the 120th day when the rats were 
sacrificed for samples collections.   
Results: Results showed that TH and MH treated rats of “cancer-preventive” groups had a lower 
tumor incidence, and a longer latency period compared to the non-treated control group. The   
tumors developed in all treated groups of preventive and therapeutic measures were lesser in 
number, size and weight compared to the non-treated control. The majority of the tumors in the 
treated groups were of better grade (grade І and ІІ) compared to the non-treated control group 
(grade ІІІ). The haematological parameters showed that varying strengths of TH, MH and HSA 
had a potentiating effect on haemoglobin, red blood cells, packed cell volume, mean corpuscular 
volume, lymphocytes and eosinophils, and a lowering effect on total white blood cells, red cell 
distribution width, polymorphs, monocytes and platelets compared to the non-treated control. 
These treatments showed no hyperglycemic effects and no body weight loss. The systemic 
administration of TH, MH  and HSA exerts anti-cancer effects through up-regulation of the 
expression of pro-apoptotic proteins such as caspase 9, Apfa-1 (apoptotic protease activating 
factor 1), p53, IFN-𝛾 (interferon gamma) and IFNGR1 (interferon gamma receptor 1), and a 
concomitant down-regulation of  the expression of anti-apoptotic proteins such as Bcl-xL (B-cell 
lymphoma-extra large), TNF-α (tumor necrosis factor alpha), COX-2 (cyclooxygenase-2), E2 
(estradiol) and ESR1 (estrogen receptor 1) at serological and or breast cancer tissues levels. 
Discussion: Our study shows that the treatment with TH and MH appears to exert cancer-
preventive and or cancer-therapeutic effects, is through the modulation tumour grading, body 
weight, haematological parameters of immune regulatory response, and modulation of pro and 
anti-apoptotic proteins of mitochondrial apoptotic pathway at serum and breast cancer tissues 
level. HSA also acts akin to honey. 
Conclusion: Tualang honey, Manuka honey and honey sugars analogue can be used as 
prophylactic cancer-preventive and cancer-therapeutic agents. The mechanism is through the 
modulation of tumour grading, haematological parameters, and the modulation of pro and anti-
apoptotic proteins at serum and cancer tissues level. 
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MEKANISME KESAN ANTIKARSINOGENIK MADU TUALANG (MT) PADA 
TERARUH KANSER PAYUDARA DALAM TIKUS 
ABSTRAK 
Madu Tualang multiflora / Tualang honey(TH) dan madu Manuka monoflora /Manuka 
honey (MH) telah dilaporkan mempunyai  kesan antimikrob, antiradang, antioksidan dan 
antikanser. Madu Tualang yang pertama belum dikaji secara meluas. Kami telah menjalankan 
satu kajian untuk menilai samada TH dan MH boleh dijadikan sebagai pencegahan [kajian 1] dan 
terapeutik [kajian 2] keatas  tikus yang telah dicetuskan dengan kanser payudara menggunakan 
karsinogen 1-metil-1-nitrosourea (MNU). Kami juga menjalankan kajian terapeutik kanser yang 
sama menggunakan gula mirip seperti madu/ honey sugars analogue (HSA), cecair yang 
mengandungi perkadaran gula dalam madu. Untuk kajian ‘pencegahan’ madu diberi kepada tikus 
7 hari sebelum cucukan MNU. Enam puluh ekor tikus betina secara rawak dibahagikan kepada 5 
kumpulan dengan 10 ekor bagi setiap kumpulan. Kumpulan '0' tidak menerima MNU dan tidak 
menerima madu (Kawalan negatif); Kumpulan 1 menerima MNU tetapi tidak madu (Kawalan 
positif). Kumpulan 2,3 dan 4 telah diberi makan TH melalui mulut/ secara oral dengan 0.2g/kg, 
1.0g/kg, and 2.0kg berat badan. Kumpulan 5 menerima 1.0 g / kg berat badan daripada MH 
Untuk kajian " terapeutik rawatan diberikan apabila tumor pertama dapat dirasakan mencapai 
saiz 10-12 mm. ", pengrupan tikus adalah serupa seperti kajian “pencegahan”  dan ditambah satu 
kumpulan tikus lagi Group 6  yang diberi makan HSA 1.0 g/kg berat badan tikus.Perkembangan 
tumor payudara dan berat badan telah dicatatkan sepanjang kajian ini. Tikus dalam semua 
kumpulan terus menerima rawatan sehingga hari ke-120 apabila mereka dikorbankan. Semasa 
autopsi, darah telah diambil untuk analisis hematologi dan serologi. Tumor tersebut dikumpulkan 
untuk pemeriksaan kasar dan ujian mikroskopi dan penentuan ekspresi/ungkapan protein pro dan 
anti-apoptotic menggunakan kaedah immunohistokimia menggunakan panel antibodi. Keputusan 
menunjukkan bahawa tikus yang dirawat TH dan MH daripada kumpulan "pencegahan kanser" 
mempunyai insiden tumor yang lebih rendah (bilangan haiwan yang menghidap tumor), dan 
tempoh pendaman yang lebih lama (waktu selang apabila tumor yang pertama muncul/terbentuk) 
berbanding dengan kumpulan kawalan yang tidak dirawat. Bilangan tumor terbentuk dalam 
kumpulan yang dirawat adalah lebih rendah daripada kumpulan kawalan yang tidak dirawat (p 
<0.05). Tidak kira sama ada madu atau mirip gula telah diberikan sebelum atau selepas 
perkembangan kanser payudara, tumor mengalami kenaikan saiz yang lebih perlahan (masing-
masing <1.48 cm dan <2 cm untuk pencegahan kanser dan kesan terapeutik) berbanding dengan 
kumpulan kawalan yang tidak dirawat (masing-masing 2.85 cm dan 3.84 cm). Berat median (g) 
dan saiz (cm) tumor dalam kumpulan dirawat juga jauh lebih rendah (p <0.05). Kenaikan berat 
badan sebenar yang signifikan diperhatikan dalam semua kumpulan dirawat berbanding dengan 
kumpulan kawalan yang tidak dirawat (p <0.05). Ujian histopatologi menunjukkan pelbagai 
corak tumor; dari benigna, DCIS (ductal carcinoma in situ), kanser invasif micropapillary dan 
jenis NOS (not-otherwise specified) / (tidak ditetapkan). Kumpulan yang dirawat menunjukkan 
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lebih pola tumor benigna berbanding dengan kumpulan kawalan yang tidak dirawat. Majoriti 
tumor dalam kumpulan yang dirawat adalah dari gred yang lebih baik (gred I dan II) berbanding 
dengan kumpulan kawalan yang tidak dirawat (gred III). Parameter hematologi menunjukkan 
bahawa dos yang berbeza bagi TH, MH dan HSA mempunyai kesan lebih besar terhadap Hb 
(hemoglobin), RBC (red blood cells)/ (sel darah merah), PVC (packed cell volume)/ (jumlah sel 
dibungkus), MCV ( mean corpuscular volume)/ (jumlah min korpuskel), limfosit dan bilangan 
eosinofil berbanding kawalan positif bukan dirawat. Rawatan dengan TH, MH dan HSA 
menunjukkan kesan berkurangan pada TWBC (total white blood cells)/ (jumlah sel darah putih), 
RDW (red cell distribution width)/ (lebar pembahagian sel merah), polimorf, monosit dan 
bilangan platelet berbanding dengan kawalan yang tidak dirawat positif. Tikus yang dirawat 
sama ada dengan dos TH, MH dan HSA tidak menunjukkan sebarang kesan hyperglycemic 
terhadap tahap glukosa darah berpuasa. Serum biokimia menunjukkan bahawa tikus yang 
dirawat dengan TH, MH dan HSA mempunyai peningkatan tahap protein pro-apoptotic; Apaf-1 
(apoptotic protease activating factor 1)/(protease apoptotic mengaktifkan faktor 1) dan IFN-y 
(interferon gamma), serta penurunan tahap protein anti-apoptotic; TNF-a (tumor nekrosis faktor 
alpha) dan E2 (estradiol), berbanding dengan kawalan positif yang tidak dirawat (p <0.05). 
Keputusan immunohistochemistry menunjukkan bahawa rawatan dengan TH, MH dan HSA 
mempunyai kesan kawal atur positif ke atas spesimen tumor untuk ekspresi/ungkapan protein 
pro-apoptotic; caspase 9, apaf-1, p53 dan IFNGR1 (interferon gamma reseptor 1), dan kesan 
kawal atur negatif terhadap ekspresi/ungkapan protein anti-apoptotic; Bcl-xL (B-cell lymphoma-
extra large)/(B-sel limfoma-tambahan besar), TNF-a, COX-2 (cyclooxygenase-2) dan ESR1 
(estrogen receptor 1), berbanding dengan spesimen tumor daripada kumpulan kawalan yang 
tidak dirawat (p <0.05). Hasil kajian kami menunjukkan dengan jelas bahawa mekanisme yang 
TH dan MH memberi kesan pencegahan kanser dan juga sebagai terapi kanser, melalui modulasi 
parameter hematologi dan serologi oleh tindak balas kawal atur imun. Pemakand oral TH dan 
MH berupaya memberikan kesan anti-kanser pada sel-sel kanser melalui pengaktifan laluan 
apoptotic mitokondria melalui kawal atur -atas ekspresi/ ungkapan protein pro-apoptotic seperti 
caspase 9, Apfa-1, p53 dan IFNGR1, dan mengiringi kawal atur- bawah ekspresi/ ungkapan 
protein anti-apoptotic seperti Bcl-xL, TNF-a, COX-2 dan ESR1. HSA mempunyai kesan yang 
serupa tetapi lebih rendah dari madu. 
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THE MECHANISM OF ANTICARCINOGENIC EFFECTS OF TUALANG HONEY 
(TH) ON INDUCED BREAST CANCER IN RATS 
ABSTRACT 
The multifloral Tualang honey (TH) and the monofloral Manuka honey (MH) have been 
reported to have antimicrobial, anti-inflammatory, antioxidant and anticancer effects. Unlike the 
Manuka honey, TH is not extensively studied. We conducted a study to evaluate the mechanisms 
of the preventive and therapeutic effects of TH and MH on experimental breast cancer induced 
rats using carcinogen 1-methyl-1-nitrosourea (MNU). We also conducted a similar cancer 
therapeutic study using Honey sugars analogue (HSA), a fluid which contains the proportion of 
sugars in honey. A total of 130 female Sprague-Dawley rats were used. Sixty female rats were 
randomly divided into 6 groups with 10 animals per group in each study. Group ‘0’ did not 
receive MNU and did not receive honey (negative Control); Group 1 received MNU but not 
honey/honey sugars analogue (positive Control). Groups 2, 3 and 4 were fed orally with 0.2, 1.0, 
2.0, 1.0 g/kg body weight of TH, and Group 5 received 1.0 g/kg body weight of MH. Group 6 
received 1.0 g/kg body weight of HSA in therapeutic study. For the “cancer-preventive” study, 
honey was given one week prior to MNU-induction and for the “cancer-therapeutic” study; 
honey was given when the first palpable tumor reached 10-12 mm in size. The development of 
mammary tumors and body weights were charted throughout the study. The rats in all treated 
groups continued to receive the treatment until the 120th day when they were sacrificed.  At 
autopsy, blood was drawn for haematological and serological analysis. The tumors were 
harvested for gross and histopathological examinations, and determination of pro and anti-
apoptotic proteins expression by immunohistochemistry using a panel of antibodies. Results 
showed that TH and MH treated rats of “cancer-preventive” groups had a lower tumor incidence 
(the number of animals developing tumors), and a longer latency period (the interval when the 
first tumor developed after MNU induction) compared to the non-treated control group. The 
number of tumors developed in the treated groups was lesser than the non-treated control group 
(p˂0.05). Regardless of honey treatment given, either before or after the breast cancer 
development, the   tumors had slower size increment (˂1.48 cm3 and ˂2 cm3 for cancer 
preventive and therapeutic effects respectively) compared to the non-treated control group (=2.85 
cm3 and =3.84 cm3 respectively). The median weight (g) and size (cm3) of the tumors in treated 
groups were also significantly lower (p˂0.05). A significant actual body weight gain was 
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observed in all treated groups compared to the non-treated control group (p˂0.05). 
Histopathological examination showed various tumor patterns; ranging from benign, DCIS 
(ductal carcinoma in situ), micropapillary and NOS (not-otherwise specified) type.  The treated 
groups showed more patterns of benign tumors compared to the non-treated control group. The 
majority of the tumors in the treated groups were of better grade (grade І and ІІ) compared to the 
non-treated control group (grade ІІІ). The haematological parameters showed that different 
dosages of TH, MH and HSA had an increasing effect on Hb (haemoglobin), RBC (red blood 
cells), PCV (packed cell volume), MCV (mean corpuscular volume), lymphocytes and 
eosinophils counts compared to the non-treated positive control. Treatments with TH, MH and 
HSA presented a decreasing effect on TWBC (total white blood cells), RDW (red cell 
distribution width), polymorphs, monocytes and platelets counts compared to the non-treated 
positive control. Various preparations of TH, MH and HSA showed no hyperglycemic effect on 
fasting blood glucose level. Serum biochemistry showed that the rats treated with TH, MH and 
HSA had an increased level of pro-apoptotic proteins; Apaf-1 (apoptotic protease activating 
factor 1) and IFN-𝛾 (interferon gamma), and a decreased level of anti-apoptotic proteins; TNF-ɑ 
(tumor necrosis factor alpha) and E2 (estradiol), compared to the non-treated positive control 
(p˂0.05). Immunohistochemistry results showed that treatments with TH, MH and HSA had a 
positive regulatory effect on the tumor specimens for the expression of pro-apoptotic proteins; 
caspase 9, apaf-1, p53 and IFNGR1 (interferon gamma receptor 1), and a negative regulatory 
effect on the expression of anti-apoptotic proteins; Bcl-xL (B-cell lymphoma-extra large), TNF-
ɑ, COX-2 (cyclooxygenase-2) and ESR1 (estrogen receptor 1), compared to the tumor specimens 
of the non-treated control group (p˂0.05). The findings of our study clearly show that the 
mechanisms by TH, MH and HSA appear to exert cancer-preventive and or cancer-therapeutic 
effects, is through the modulation of haematological and serological parameters of immune 
regulatory response. The systemic administration of TH, MH  and HSA exerts anti-cancer effects 
on cancer cells via the activation of the mitochondrial apoptotic pathway through up-regulation 
of expression of pro-apoptotic proteins such as caspase 9, Apfa-1, p53 and IFNGR1, and a 
concomitant down-regulation of  the expression of anti-apoptotic proteins such as Bcl-xL, TNF-
α, COX-2 and ESR1. 
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CHAPTER 1 
 
INTRODUCTION 
 
Brest cancer is an abnormal and uncontrolled growth of breast epithelial cells, which 
invade the ducts and lobules of the tissue. It has been recognized as the second most common 
cancer after lung cancer, the fifth most common cause of cancer death and the leading cause of 
cancer death in women worldwide, surpassing the cervical cancer (Parkin and Fernandez, 2006; 
Ferlay et al., 2010; Jemal et al., 2010; Pinder, 2010; Jemal et al., 2011; Vivien V Ng et al., 
2014). In Malaysia, a recent report shows breast cancer as the most frequently diagnosed cancer 
and the International Agency for Research in Cancer (GLOBOCAN) estimated the ASR (age-
standardized rate) of breast cancer in Malaysia as 38.7 per 100,000 with 5410 new cases in 2012 
(Yip et al., 2014). Considering demographic changes with the lack of access to early diagnosis 
and treatment in the developing world, it is estimated that the mortality rate from breast cancer 
will increase by over 100% in developing countries by 2020 (Howell, 2010).  
The current treatment modalities against breast cancer include surgery, radiation therapy, 
hormone therapy and widely used chemotherapy (Turner and Jones, 2008). Chemotherapy drugs 
had an obstacle of collateral damage to the normal cells and tissues (Yaacob and Ismail, 2014). 
The relapse after chemotherapy, second primary tumours and resistance to chemotherapeutic 
drugs have also been reported in breast cancer patients (Tsao et al., 2004; Bansal et al., 2012; 
Raffoul et al., 2012b). This urges to explore alternative measures for cancer therapy and 
prevention. The alternative measure to the recent modalities and some of their unavoidable side 
effects, is the use of natural products such as honey (Othman, 2012a; Othman, 2012c; Ahmed 
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and Othman, 2013a). This study was aimed to evaluate the cancer-preventive and cancer-
therapeutic activity of honey against breast cancer in in vivo. “Cancer-preventive” is termed 
when honey was given one week prior of tumour induction, while “cancer-therapeutic” termed 
when honey treatment was given after breast cancer development. 
Honey has been used as a traditional medicine to cure several ailments since ancient 
times in different cultures (Allsop and Miller, 1996). Honey has been shown to have anti-
inflammatory (Cooper et al., 2001),  anti-microbial (Sherlock et al., 2010), antioxidant (Al-
Mamary et al., 2002; Erejuwa et al., 2010b; Erejuwa et al., 2012b) anti-tumour (Swellam et al., 
2003; Tomasin and Gomes-Marcondes, 2011; Othman, 2012b),  and antidiabetic effects 
(Erejuwa et al., 2010a; Erejuwa et al., 2011). Honey has also been demonstrated as a natural 
anticancer vaccine (Othman, 2012a; Othman, 2012c). For that reasons, a type of Malaysia’s own 
local honey called Tualang honey (TH) has been selected for this study. To capitalize the 
understanding of its efficacy at broad spectrum level, effects of Manuka honey (MH) and Honey 
sugars analogue (fructose, glucose, maltose and sucrose) were also investigated for cancer-
prevention and cancer-therapy in breast cancer induced animal models. 
Tualang honey (TH) is a multi-floral jungle honey. It is produced by “Apis dorsata” bee 
species which build their hives high on Tualang trees (Kompassia excelsa), found mainly in 
Malaysian tropical rainforests (Erejuwa et al., 2010b; Mohamed et al., 2010a; Ahmed and 
Othman, 2013b). Published data has shown that TH exhibits antimicrobial (Nasir et al., 2010; 
Sukur et al., 2011), anti-inflammatory (Bashkaran et al., 2011), antioxidant (Mohamed et al., 
2010b; Khalil et al., 2012; Tan et al., 2014) and antidiabetic effects (Erejuwa et al., 2010b; 
Erejuwa et al., 2012a). TH has been shown to have anticancer effects against oral squamous cell 
carcinoma (Ghashm et al., 2010b),  human osteosarcoma cell lines (Ghashm et al., 2010b), 
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human breast cancer cell lines MCF-7 cells (Fauzi et al., 2011), cervical cancer cell lines (Fauzi 
et al., 2011) and leukemic cell lines K562 (Rosline et al., 2010). Recent studies have shown that 
TH exhibits breast anticancer activity, reduces tamoxifen-induced cytotoxicity in vitro and 
demonstrates preventive effects against breast cancer in vivo (Kadir et al., 2013; Yaacob et al., 
2013; Yaacob and Ismail, 2014). 
Manuka honey (MH) unlike Tualang honey is a mono-floral honey. It is produced by 
honey bees from nectars of Manuka bush (Leptospermum scoparium) throughout New Zealand 
and Australia (Yao et al., 2003). Published literature on Manuka honey indicates its numerous 
therapeutic properties against several ailments (Russell et al., 1990; Molan, 2001a; Visvadia et 
al., 2008; Old, 2013; Kamaratos et al., 2014), including breast cancer (Fernandez-Cabezudo et 
al., 2013). Literature lacks reports on HSA, namely honey sugars analogue (fructose, glucose, 
maltose and sucrose), and has not been previously reported. Glucose and fructose account for 
major part of honey (Shin and Ustunol, 2005; Ahmed and Othman, 2013b); exhibit anti-
mutagenic and anti-cancer effects in different models (Wang et al., 2002; Speicher et al., 2010). 
This supports the hypothesis that general honey sugars analogue may exhibit anticancer activity.  
Breast cancer induction using carcinogen MNU (1-methyl-1-Nitrosourea) in female rats 
is one of the most frequently used animal models. It has several advantages such as 1) reliability 
of tumour induction, 2) organ site specificity, 3) the tumour developed is of ductal origin, 4) 
resembles human mammary carcinoma, and 5) easy to examine tumour promotion and 
histopathological characterizations (Welsch, 1985; Thompson and Adlakha, 1991; Thompson et 
al., 1995; Russo and Russo, 2000; Tsubura et al., 2011). This is the reason that MNU-induced 
mammary carcinoma in the Sprague–Dawley rat model was chosen in this study. 
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The potential “preventive” and “therapeutic” effects of TH, MH and HAS are based on 
these parameters; the tumour growth characteristics; the histological features, the tumour grades 
and the histological patterns were evaluated in the present study. Assessment of histological 
grading of breast carcinoma along with the histological type have pivotal importance for the 
prognosis to determine the appropriate treatment and to anticipate the post-treatment survival in 
breast cancer (Harvey et al., 1995; Boiesen et al., 2000; Dalton et al., 2000; Ignatiadis and 
Sotiriou, 2008). 
Broad spectrum pre and post treatment studies have revealed a deranged or altered full 
blood count pattern in breast cancer patients (Sheikh et al., 2011; Akinbami et al., 2013). It is 
well-established that the functional status of the immune system at haematological and 
serological level has direct influence on breast cancer (Hamidullah et al., 2012). Research has 
shown that honey feeding significantly modifies the haematological parameters in normal 
individuals (Al-Waili et al., 2006; Fiorani et al., 2006). Similarly, Manuka, Pasture, Nigerian 
Jungle and royal jelly honeys have been found to increase immune factors such as IL- 1β, IL-6 
and TNF-α production (Tonks et al., 2001; Timm et al., 2008; Fukuda et al., 2011). This study 
also addresses the haematological and serological response modification by TH, MH and HSA 
against breast cancer, which has not been reported yet. 
The effects of TH, MH and SM administration on the expression of pro and anti-apoptotic 
proteins in tumour specimens were also evaluated to elaborate their mechanism of action. 
Apoptosis is a program that leads to cell death. Apoptotic cell death of cancer cells is the prime 
purpose of cancer treatment and plays a vital role in immune response resolution, and 
elimination of dysfunctional cells (Muradian and Schachtschabel, 2001; Pollack et al., 2002). 
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Honey induces apoptosis via regulation of pro and anti-apoptotic proteins of intrinsic apoptotic 
pathway (Jaganathan and Mandal, 2010; Fauzi et al., 2011; Ahmed and Othman, 2013a). 
 
1.1     Objectives 
 
1.1.1 General objective 
To evaluate the cancer-preventive (study I) and cancer-therapeutic effects (study II) of 
Tualang (TH) and Manuka (MH) honeys on MNU-induced breast cancer rats, and to understand 
the underlying mechanisms. Concomitantly, the cancer-therapeutic efficacy of honey sugars 
analogue (HAS) was also investigated. 
 
1.1.2 Specific objectives 
 
1. To determine the growth inhibitory effects of TH, MH and HSA (tumour incidence, 
latency, multiplicity, size and weight). 
2. To determine the effects of TH, MH and HSA administration on tumour grading, 
patterns and haematological parameters of rats.  
3. To determine the effects of TH, MH and HSA on the expression of pro-apoptotic 
proteins; Apaf-1 (apoptotic protease activating factor 1) and IFN-γ (interferon 
gamma), and anti-apoptotic proteins; TNF-α (tumour necrosis factor alpha) and E2 
(estradiol) at serum level.  
4. To determine the effects of TH, MH and HSA on the expression of proapoptotic 
proteins; caspase-9, Apaf-1, p53, IFNGR1 (interferon gamma receptor 1), FASLG 
(Fas ligand) and FADD (Fas-associated via death domain), and anti-apoptotic 
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proteins; Bcl-xL, (B-cell lymphoma-extra large), TNF-α, COX-2 (cyclooxygenase-2) 
and ESR1 (estrogen receptor 1) at cancer tissues level. 
The above objectives are conducted for both studies, study 1 where honey treatment was 
given one week prior to cancer induction and for study 2 where honey treatment was 
given when the first breast cancer mass reached 10-12mm in size. 
 
1.2    Problem statement 
Chemotherapy drugs cause collateral damage to the normal cells and tissues. Honey is a 
probable alternative as an adjunct to conventional treatment  
 
1.3    Hypothesis 
Tualang and Manuka honeys have anti breast cancer activity. The mechanism of action is 
through certain regulatory genes of cellular growth.  
 
1.4    Significance of research 
This study could provide information on the benefits of Tualang and Manuka honeys in 
prevention and therapy of breast cancer. The exploration of the mechanisms of their action will 
probe the different molecular targets and pathways involved, possibly to facilitate the use as 
complementary targeted-therapy against this cancer. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1    Breast cancer 
Generally, cancer is an abnormal growth of cells. It starts as an onset from a single 
transformed cell.  Its genesis is characterized by the swift proliferation, invasion and metastasis 
(Shishodia et al., 2003). This dynamic process is activated by various carcinogens, tumour 
promoters and inflammatory agents. The whole modulation is controlled through transcription 
factors, pro-apoptotic proteins, anti-apoptotic proteins, protein kinases, cell cycle proteins, cell 
adhesion molecules, cyclooxygenase-2 (COX-2) and other molecular targets (Wang and 
Lenardo, 2000; Shishodia et al., 2003; Aggarwal and Shishodia, 2006). 
  Breast cancer is an abnormal and uncontrolled growth of epithelial cells involving the 
ducts and lobules of the breast tissue. It develops in cells from the lining of  ducts and the lobules 
which supply milk. Mammary carcinoma usually results from the new formation of cells or 
neoplasm in ducts and lobules, which undergo rapid transformation and growth and eventually 
form a lump or mass which is known as tumour (Damjanov, 2006; Banin Hirata et al., 2014; 
NCI, 2014). Breast tumours are classified histologically based on the location of origin. Cancers 
developing from the ducts are known as ductal carcinomas, whereas those developing from 
lobules are known as lobular carcinomas. The ductal tumours represent 80% of tumours and 
lobular tumours account for 10 to 15% of cases. Other subtypes represent less than 10% of cases 
diagnosed per year (Banin Hirata et al., 2014). 
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  Neoplasia or tumours arising from breast tissue are commonly adenocarcinoma of the 
cells lining the terminal duct lobular unit. Tumours can be classified into benign or malignant.  
Benign tumours are identified as localized growth with no distant spread or metastasis to other 
body parts. The malignant tumours are known as cancer which invade stroma and infiltrate or 
metastasize to other parts of the body such as  lymph nodes, bone, liver, and lung (Weigelt et al., 
2010; Beaumont and Leadbeater, 2011; Peto et al., 2012) . Other sites of metastasis may include 
the skin and brain (Beaumont and Leadbeater, 2011; Peto et al., 2012). 
Breast cancer development usually involves progression through a series of intermediate 
processes that start from ductal hyperproliferation, and followed by subsequent evolution to 
carcinoma in situ, invasive carcinoma and finally into metastasis (Polyak, 2007). The process of 
metastasis comprises of a series of sequential steps and failure to complete any of these steps will 
arrest this process (Fidler, 2003). Metastasis starts with the local invasion of surrounding host 
tissue cells originating from the primary tumour and continues until the tumour cells invade and 
intravasate into lymphatic vessels or blood (Hunter et al., 2008; Talmadge and Fidler, 2010). The 
tumour cells are disseminated via the lymphatic vessels or the blood stream to distant organs. 
Consequently, the tumour cells undergo cell cycle arrest and adhere to capillary beds within the 
target organs. Before extravagating into the organ parenchyma, these cells proliferate and 
promote angiogenesis within these organs (Hunter et al., 2008). These tumour cells must 
simultaneously evade the host’s apoptotic signals and immune response in order to survive and 
proliferate (Fidler et al., 1978; Hunter et al., 2008). When the tumour cells succeed in 
completing these steps, the process can be repeated to produce secondary metastases or 
metastasis of metastases (Fidler, 2003; Talmadge and Fidler, 2010). 
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2.1.1    Incidence and prevalence 
Breast cancer is recognized as the second most common cancer after lung cancer, the 
fifth most common cause of cancer death and the leading cause of cancer death in women 
worldwide (Parkin and Fernandez, 2006; Ferlay et al., 2010; Jemal et al., 2010; Pinder, 2010; 
Jemal et al., 2011; Ferlay J et al., 2013). In 2013, breast cancer has been continued to be the 
most common female cancer and its incidence is still on rise (Vivien V Ng et al., 2014). In 
Malaysia, a recent report shows breast cancer as the most frequently diagnosed cancer, and the 
International Agency for Research in Cancer (GLOBOCAN) 2012 estimated the age 
standardized rate (ASR) of breast cancer in Malaysia as 38.7 per 100,000 with 5410 new cases in 
2012 (Yip et al., 2014). Breast cancer is among the most common four types of cancer followed 
by lung, female breast, bowel and prostate cancer (Figure 2.1) (Ferlay J et al., 2013). A report 
generated from the Malaysian National Cancer Registry (NCR) department lists breast cancer at 
top among the five leading cancers in general population of Malaysia (Figure 2.2) (Ariffin and 
Saleha, 2011). 
  In many developing countries including Malaysia, the incidence of breast cancer is now 
rising sharply. More than half of incident cases occur in the developing world and combined with 
still high case-fatality rates (Hisham and Yip, 2004; Shulman et al., 2010; Yip et al., 2014). In 
Peninsular Malaysia, data from 2003 to 2005 shows that the incidence was highest among 
women of age between 50 to 60 years old, and the incidence of breast cancer among women in 
Malaysia is still lower than most of Western countries or developed world (Chye et al., 2008). 
Considering demographic changes with the lack of access to early diagnosis and treatment in the 
developing world, there will be a continuous marked increase in the incidence and mortality
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Figure 2.1: The most commonly diagnosed cancers worldwide. Source reference (Ferlay J et al., 
2013). 
 
Figure 2.2: The most commonly diagnosed cancers in Malaysia. Source reference (Ariffin and 
Saleha, 2011). 
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from breast cancer. It is estimated that this mortality rate from breast cancer will increase by over 
100% in developing countries by 2020 (Howell, 2010). 
 
2.1.2    Risk factors 
 
Several research studies have explored a wealth of risk factors among women in different 
countries which impact on the countries’ incidence and prevalence. These risk factors can be 
classified as demographic-socioeconomic related, genetic-racial-related, hormone-reproductive, 
behavior-related and lifestyle-related. Many other factors, including prenatal conditions, physical 
activity, diet, body mass index, estrogen exposure, depression and quality of life have been 
demonstrated as breast cancer risk factors. A positive family history has also been described as 
one of the main risk factors (Ruder et al., 2008; Press and Pharoah, 2010; Ostad and Parsa, 
2011). 
Hormonal conditions are also considered pivotal among the risk factors. Prolonged 
exposure to higher concentrations of endogenous estrogen; which is thought to be controlled and 
modulated by menarche, pregnancy and menopause; causes to increase the risk of breast cancer. 
Higher testosterones level has also shown some higher rate of breast cancer in some studies, 
although not in all of them. Younger age of menarche and older age of first full-term pregnancy 
have also been found to be associated with a higher risk of breast cancer. Research has shown an 
increased risk of breast cancer in oral contraceptive users, whereas some other researchers report 
no significant difference. It has also been reported that long term use of postmenopausal 
hormone therapy is associated with higher risk of breast cancer. Exposure to environmental toxic 
organochlorines agents such polychlorinated biphenyls (PCB's), dioxins, organochlorine 
pesticides have been demonstrated to increase the risk of breast cancer. Age and gender are 
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considered among the strongest risk factors for breast cancer. Breast cancer occurs 100 times 
more frequently in women compared to men. Incidence rates increase with age until about the 
age of 45 to 50 which are thought to be more susceptible. In Malaysia, more than half of new 
cases of breast cancer are found to be diagnosed in women under the age of 50 years (Hisham 
and Yip, 2004). 
Ethnic difference has been described as another factor affecting breast cancer prevalence. 
For instance, in United States, breast cancer prevails more among white people. Much of these 
differences arise from social conditions and lifestyle factors. There are marked variations in 
breast cancer incidence and mortality among different countries. Women with higher 
educational, occupational and economic level are at higher risk because of the reproductive 
patterns, including age of first birth and age of parity. Ethnic differences in estrogen and 
progesterone receptor subtypes have also been documented as important factors that may affect 
the probability of breast cancer in women (Setiawan et al., 2009; Ostad and Parsa, 2011). 
Familial history of breast cancer carrying gene mutations in breast cancer related genes such as 
gene 1 (BRCA1) and gene 2 (BRCA2), may also cause women at high risk to develop breast 
cancer (Martin and Weber, 2000). Research has also shown that risk factors may include the 
excessive use of alcohol, obesity and physical inactivity which account for 21% of all breast 
cancer deaths worldwide (Danaei et al., 2005). It has also been reported that reduction in breast 
size reduces the risk for breast cancer (Jansen et al., 2014). 
A number of lifestyle and genetic factors have been shown to cause an increased risk of 
breast cancer in Malaysian women. These risk factors include, family history, nulliparity, not 
breastfeeding and use of oral contraceptives are observed to be associated with a greater risk of 
breast cancer in Malaysian women. The other risk factors are not significantly associated such as 
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age at menarche and first childbirth. Genetic predisposition may also play a role in the aetiology 
of breast cancer. It has been estimated that approximately 15% of breast cancer patients in 
Malaysia report family history of breast and ovarian cancers, with the most significant genetic 
predisposition of genes identified are BRCA1 and BRCA2 (Yip et al., 2014). 
 
2.2    Morphogenesis and structure of the normal human breast 
The breast or mammary gland is one of the defining characteristics among mammals. 
Rudimentary mammary glands or breasts develop in the embryo and grow after birth with body 
growth. The gland undergoes a rapid expansion with the ductal tree growing and branching until 
the limits of the fat pad at puberty in response to steroid hormones. The glandular tissue 
undergoes a round of proliferation and differentiation during each menstrual cycle and caused 
ductal tree to produce tertiary branches and alveolar structures (Figure 2.3). The breast develops 
fully at pregnancy when milk-producing lobuloalveolar structures develop. The lactating breast 
comprises a branched network of epithelial ducts leading from the nipple and expanded to 
secretory alveoli embedded within an adipocyte rich stroma (Figure 2.4). (Shackleton et al., 
2006; Stingl et al., 2006; Sleeman et al., 2007; Taddei et al., 2008).  
The detailed anatomy of breast reveals that it is composed of fifteen to twenty lobes and 
each lobe further dividends into smaller sections of lobules.  Lobules contain lactiferous ducts 
and milk-producing glands that lead the lobules to the nipple as a passage for milk delivery. 
Further, fatty tissues and fibrous stroma or connective tissues that contain blood capillaries and 
nerves, surround both lobules and ductal units (Ganschow, 2004). The lobular structure is found 
to be comprised of ducts that are divided into club-shaped terminal end buds, and these buds 
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later form two smaller structures called alveolar buds. These alveolar buds surround the terminal 
ducts and form the terminal ductal-lobular unit (TDLU). 
TDLU is the functional unit of human mammary glands and it contains an abundance of 
highly proliferative population of stem cells (Russo and Russo, 1978). At extended level, ducts 
divide into ductules, lobules and TDLU, comprising of epithelium. The epithelium seems to be 
comprised of two cell types, outer basal cells and inner luminal cells (Figure 2.5). The basal cells 
consist of differentiated myoepithelial cells and may have many features of both smooth muscle 
and epithelium. This compartment has been shown also to exhibit mammary stem cells 
(Shackleton et al., 2006; Stingl et al., 2006; Sleeman et al., 2007; Taddei et al., 2008). These 
stem cells further give rise to the mature epithelium of myoepithelial or the luminal lineage. The 
luminal cells are mostly comprised of ductal or alveolar milk-secreting cells and a subpopulation 
of these cells are hormone receptor-expressing cells (Sleeman et al., 2007). 
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Figure 2.3: Development of the breast ductal tree after birth. Source reference (Sternlicht, 
2006). 
 
 
 
 
 
 
  
 
 
  Figure 2.4: Structure of normal human breast. Source reference (Martini et al., 2009). 
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Figure 2.5: Structure of the mammary gland. Terminal ductal–lobular unit (TDLU) comprised of 
ductal cells. The stroma is composed of adipocytes (fatty tissue) and fibroblasts. Two primary 
types of cells in normal ducts: outer contractile myoepithelial and inner columnar luminal cells 
are also shown. A putative progenitor or stem cell is also indicated. Source reference (Dimri et 
al., 2005). 
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2.3    Carcinogenesis of human breast cancer 
Carcinogenesis results from the interaction of exogenous factors leading to initiation of 
endogenous process. This process triggers the genetic and or epigenetic alteration of multiple 
genes (Kyrtopoulos, 2006). These genetic alterations are produced by the exposure of somatic 
cells or normal stem cells to various exogenous factors which either may be chemically- induced 
such as exposure to polycyclic aromatic hydrocarbons (PAH), or physically-induced such as 
ionizing radiation causing mutations in  the stem cells. This is considered to be the first step in 
carcinogenesis, where the cellular genome undergoes mutations for neoplastic development. 
The somatic genetic changes in cells that contribute to tumour development usually 
involve sequential mutation of different classes of genes such as proto-oncogenes, tumour 
suppressor genes, genes involved in cell cycle regulation, and genes that play roles in 
maintaining normal genomic stability. The human DNA sequences responsible for 
transformation are called oncogenes. Although the activation of more than one oncogene appears 
to be essential for neoplastic transformation, but the data imply that initiation may be induced 
with one hit kinetic. The activation of these oncogene results in the production of proteins which 
ultimately trigger the increased transformation and proliferation of genetically-insulted 
neoplastic or tumour cells (McPherson et al., 2000, Croce, 2008).  
At extended level, biochemical interactions between tumour gene mutations may 
destabilize the genome, which compromise control of cell signaling, proliferation and 
differentiation interfering with the normal interaction of cells in tissues (Karp and Broder, 1995; 
Osborne et al., 2004). Mutated genes are supposed to cause inheritable spontaneous changes in 
DNA structure by affecting the DNA replication and cell divisions.  These changes result in 
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imbalance to the rate of cell proliferation and cell death, thus increasing the cellular proliferation 
of the mutated cells with reduced programmed cell death mechanism. Many cell cycle 
generations of mutated cells cause the formation of excessive amount of new abnormal cells 
known as neoplasia or tumours (Bertram, 2000). 
Carcinogenesis is a multistep process and can be divided into three main stages; 
initiation, promotion and progression (Figure 2.6). Initiation phase involves one or more 
irreversible cellular DNA-damaged changes arising spontaneously or induced by exposure to a 
carcinogen. This genetic change results in mutations activation. This is the first step in 
carcinogenesis where the mutations result in neoplastic development. During promotion, the 
mutated initiated cells are stimulated to undergo further proliferation by upsetting the cellular 
balance to form a new population of cells, which may be a benign or preneoplastic lesion. The 
progression is the advanced phase through which successive changes in the neoplasm give rise to 
increasingly malignant sub-populations or malignant cells. Molecular mechanisms of tumour 
progression are not fully known, but chromosomal and genes level aberrations or mutations are 
thought to be involved (Barrett, 1993).  After the first exposure to the carcinogens, it may take 
many years or even decades for the promotion and progression to be completed until the cancer 
formed (Tsao et al., 2004). 
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        Figure 2.6: Overview of breast cancer carcinogenesis. Source reference (LaMorte, 2005). 
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2.4    Pathogenesis of human breast carcinoma 
Breast cancer arises from a series of mutations that may accumulate over years (Hayat, 
2005; Kwei et al., 2010). Several studies have demonstrated that the development of breast 
cancer has been attributed to numerous factors, including internal such as endocrine or hormonal 
related factors and external such as genetic factors, early menarche, late menopause, parity and 
several others (Russo et al., 2000). 
The site of origin for breast cancer has been proclaimed to arise from lobular unit that 
comprises the most undifferentiated structure, and is also the origin site for the most common 
type of malignancy in human breast known as invasive ductal carcinoma (Russo and Russo, 
1978; Wellings, 1980; Russo et al., 1998; Russo et al., 2000). The high proliferative activity and 
fragility upon genetic alteration by exogenous mutagenic influence of lobules, makes it highly 
susceptible for preneoplastic and neoplastic processes (Russo et al., 2000). 
Generally, cancer cells exhibit six characteristics to ensure their survival namely (1) self-
sufficiency in growth signals, (2) insensitivity to apoptosis or cell death (3) uncontrolled 
replicative potential, (4) resistance to growth-inhibitory factors (5) sustained angiogenesis and 
(6) tissue invasion and metastasis (Hanahan and Weinberg, 2000; Liu et al., 2005) . One of the 
key hallmarks of breast carcinoma is the loss of the ability to control growth within organized 
bilayered ducts or lobules (Mallon et al., 2000; Guinebretière et al., 2005). Normal mammary 
ducts, lobules and alveoli consist of a single layer of epithelial cells lining the lumen and 
myoepithelial cells lining the basement membrane (Mallon et al., 2000; Polyak, 2001; 
Guinebretière et al., 2005). The close cellular contact of luminal and myoepithelial cells enables 
autocrine and paracrine interaction potentially mediated by chemokines either between luminal 
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and epithelial cells or between luminal epithelial cells and stromal cells including fibroblasts, 
adipocytes, macrophages, lymphocytes, eosinophil granulocytes and endothelial cells (Polyak, 
2001). An aberrant proliferation of epithelial cells and myoepithelial cells lead to the formation 
of benign lesions such as fibrocystic diseases, fibroadenomas, epithelial hyperplasia, sclerosing 
lesions and tubular adenomas, and intraductal papillomas (Courtillot et al., 2005; Bateman, 
2010). Generally, these types of lesions are non-detrimental, but have the potential to develop 
into breast carcinoma in situ. 
Carcinoma in situ is a pre-malignant proliferation of the breast epithelial cells confined 
within the basement membrane (Russo and Russo, 2000; Thompson and Singh, 2000), and can 
be classified as ductal carcinoma in situ (DCIS) which is originated from the ductal region or  
lobular carcinoma in situ (LCTS), originating from the lobular region (Meijnen et al., 2006; 
Pinder, 2010). DCIS exhibited several histological subtypes including cribriform, comedo, solid 
and micropapillary, and LCIS does not possess any one (Mallon et al., 2000; Guinebretière et al., 
2005). In addition, both carcinomas in situ are known to be precursor of invasive carcinoma 
(Polyak, 2001; Hanby, 2005; Polyak, 2007) (Figure 2.7). 
Invasive carcinoma retains similar characteristics as carcinoma in situ, but the tumour 
cells breach the basement membrane invading the surrounding tissues (Russo and Russo, 2000; 
Bateman, 2010) (Figure 2.7). Invasive ductal carcinoma (IDC) which is the most common breast 
carcinoma in humans has been histologically classified as special-type and Not-otherwise 
specified (NOS) type. It is estimated that 75% of breast carcinoma cases in humans are 
diagnosed as IDC-NOS (Hanby, 2005), as the tumour exhibits no specific characteristics. The 
remaining special-type of invasive carcinoma which have distinctive characteristics such as 
tubular carcinoma, cribriform carcinoma, solid papillary carcinoma and many more, rarely occur  
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Figure 2.7:  Pathogenesis of breast cancer. Source references (Polyak, 2001; Hanby, 2005; 
Polyak, 2007). 
Normal duct 
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Invasive ductal carcinoma 
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in breast carcinoma cases. In advanced stage, breast carcinoma has been seen to be metastasized 
to a distant organs such as liver, lungs, brain, adrenal gland and bones through the lymphatic and 
systemic vascular invasion (Mallon et al., 2000; Hanby, 2005). 
 
2.5    Molecular classification of breast cancer 
Breast cancer is a heterogeneous disease and comprised of numerous distinct cell types 
with different clinical, histological and biological features. Thus, classification of breast cancer 
cannot be limited to the localization and the proliferative extent of the tumours. The research in 
recent era has classified the breast cancer on molecular basis by utilizing different molecular 
techniques and comprehensive genes profiling analysis. The molecular classification of breast 
cancer has revealed five major subtypes of breast cancer; luminal B, HER2+/ER–, basal-like, 
luminal A and normal breast–like (Perou et al., 2000; Sorlie et al., 2001; Lakhani, 2002; Hu et 
al., 2006; Schnitt, 2010). These molecular differences have brought revolutionary changes with 
distinct clinical outcomes and response to treatments. Amongst the molecular subtypes, luminal 
A-type tumours have been demonstrated as the low-grade tumours with the best prognosis 
(Sorlie et al., 2001). The luminal B type tumours have been described as more aggressive with 
more proliferation, and are of high-grade. Basal-like tumours show relatively poor prognosis 
expressing some molecules found in the myoepithelial/ basal compartment of normal breast 
tissues. These tumours are usually negative for HER2 (human epidermal growth factor receptor 
2) and ER (Estrogen Receptor) (Lakhani, 2002; Vuong et al., 2014). The recent advances in 
molecular subtypes of breast cancer have made easy the choice of therapeutic regimen for the 
patients, and ensure more specificity to the target specific treatment. 
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2.6    Cancer-preventive studies 
The purpose of cancer-prevention or chemoprevention is to interfere with the basic 
process of carcinogenesis through chemical agents or regimens that may block the initial 
neoplastic induction, resulting in prevention of the progression of transformed cells into 
malignant types.   The other purpose is to prevent the development of second primary tumours 
that may arise from patients who had already been cured from the initial cancer (Tsao et al., 
2004) .  The multistep carcinogenesis process over a long period of time allows the possibility to 
be intervened through natural or synthetic chemopreventive agents at various stages of 
carcinogenesis (Raffoul et al., 2012b).  The long latent period of cancer formation might be the 
reason why the high occurrence of breast cancer is among the elderly women, who might have 
been exposed to potential anti-carcinogenic agent in their early lifetime (Raffoul et al., 2012b). 
The concept of cancer-preventive studies is to give the potential chemopreventive agents 
to the subjects who have been exposed to carcinogens at their early age or any stage. Several 
cancer-preventive or chemoprevention studies to date have applied this principle (Raffoul et al., 
2012b).  The potential preventive agents can be given either before or shortly after exposure to 
the carcinogen, depending on the purposes of trials (Mehta, 2000; Raffoul et al., 2012b). Results 
obtained from the experimental models can later be classified as an anti-initiating agent if the 
intervention is during the initiation stage or anti-promoting agent if the intervention is during the 
promotion and progression of carcinogenesis.  The carcinogenesis interventions must have the 
purpose of enhancing or improving the protective physiological mechanism against the disease 
(Mehta, 2000; Raffoul et al., 2012b).  
